Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Open House Discount Contracts 2023-04

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Urapidil (C02ca06) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Baricitinib (L04aa37) as Part of a So-Called Open House Model.

Purchase of Medical Instruments, their Renewal

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Tamsulosin/Dutasteride (Atc Code Who: G04ca52)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Secukinumab (L04ac10) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Mepolizumab (R03dx09) as Part of a So-Called Open House Model.

Dynamic Purchasing System for Medical Equipment for Eye Diagnostics

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Cinacalcet (Atc Code Who: H05bx01)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Amifampridine (N07xx05) as Part of a So-Called Open House Model.